-- Par Pacific (PARR) 週二晚間公佈了第一季調整後每股收益為 0.78 美元，扭轉了去年同期虧損 0.94 美元的局面。 FactSet 調查的分析師此前預期每股收益為 0.99 美元。 截至 3 月 31 日的第一季度，公司營收為 18.2 億美元，高於去年同期的 17.5 億美元。 FactSet 調查的分析師先前預期營收為 17.8 億美元。 Par Pacific 的股價在盤後交易中下跌超過 7%。
Related Articles
Asia
Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug
Simcere Pharmaceutical (HKG:2096) received Chinese regulatory approval to begin clinical trials of SIM0613, according to a Hong Kong bourse filing Wednesday.The injection is intended to treat advanced solid tumors and is licensed to Ipsen Pharma in regions outside Greater China.
$HKG:2096
Asia
Meitu Records 30% Rise in Paying Subscribers
Meitu (HKG:1357) said the number of paying subscribers using its platform grew 30% year on year to 17.90 million as of end March, according to a Hong Kong bourse filing Wednesday.Paying subscribers for the company's productivity tools grew 53% to 2.34 million, while leisure app subscribers increased 27% to 15.56 million, the firm said.The company's core revenue grew 34.3% year on year to 852 million yuan, while other businesses remained "stable overall."The company's annual recurring revenue for AI-driven productivity apps stood at 580 million yuan as of March, a 56% increase from a year earlier.
$HKG:1357
Asia
Yidu Tech Unit Wins SG$2.3 Million Singapore Healthcare Project
Yidu Tech (HKG:2158) said its subsidiary EVYD Research Private Limited won a contract from Singapore Health Services for the implementation and support of Dr Buddy, according to a Wednesday Hong Kong bourse filing.The total project amount is about SG$2.3 million.
$HKG:2158